Table 5.

Comparative analysis of AITL patients based on the remission status at the time of allo-HCT

	CR1 (N = 33)		CR > 1 (N = 75)		PR (N = 90)		Refractory (N = 38)
Outcomes	N	Prob (95% CI)	N	Prob (95% CI)	N	Prob (95% CI)	N	Prob (95% CI)
NRM	33		75		90		38
1-year		6 (1–17)%		20 (12–30)%		20 (13–29)%		24 (12–38)%
2-year		13 (4–26)%		29 (19–40)%		25 (17–35)%		30 (16–45)%
3-year		17 (6–32)%		31 (21–43)%		25 (17–35)%		30 (16–45)%
4-year		17 (6–32)%		36 (25–49)%		33 (22–44)%		30 (16–45)%
Progression/ relapse	33		75		90		38
1-year		15 (5–29)%		13 (7–22)%		14 (7–21)%		29 (16–44)%
2-year		25 (12–41)%		16 (9–26)%		19 (11–28)%		29 (16–44)%
3-year		25 (12–41)%		18 (10–28)%		19 (11–28)%		32 (18–48)%
4-year		25 (12–41)%		18 (10–28)%		21 (12–30)%		32 (18–48)%
PFS	33		75		90		38
1-year		79 (63–91)%		67 (56–77)%		66 (56–76)%		47 (32–63)%
2-year		62 (45–78)%		54 (43–66)%		56 (45–66)%		41 (26–57)%
3-year		58 (41–75)%		50 (38–62)%		56 (45–66)%		38 (23–54)%
4-year		58 (41–75)%		45 (33–58)%		47 (36–58)%		38 (23–54)%
Overall survival	33		75		90		38
1-year		88 (75–97)%		73 (63–83)%		71 (61–80)%		63 (47–78)%
2-year		78 (62–90)%		62 (51–73)%		59 (48–69)%		52 (36–67)%
3-year		70 (52–85)%		58 (46–70)%		57 (47–68)%		52 (36–67)%
4-year		70 (52–85)%		54 (41–66)%		50 (39–62)%		52 (36–67)%

CR complete response, PR partial response, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival